Asia’s biotech scene is accelerating, and for those in ADCs, TCEs, TPDs, BsAbs, and RLTs, the shift from innovation to execution is well underway. With supportive clinical infrastructure, regulatory incentives, and strong global pharma interest, this summit is the go-to platform to connect, partner, and move pipelines forward.
Inside, you’ll discover:
- Why global big pharma is actively scouting de-risked assets in Asia - and how that shapes your business development strategy
- Best practices for One-on-One Partnering™ and how to prepare for productive, high-value meetings
- Insights into ADC, TCE, TPD, and RLT deal trends, regional case studies, and what’s next for emerging assets
Access your free copy to see how this summit opens the door to partnering and licensing in Asia’s targeted therapy boom.
About Hanson Wade Group - Targeted Therapies Partnering & Licensing Summit Asia
For ADCs, BsAbs, TCEs, TPD and RLT: The Hyper-Aligned Partnership Event Delivering Better Access to Global Big Pharma Seeking Innovation in Asia
With fast, cost-effective clinical infrastructure, generous government incentives, and simplified regulatory pathways, Asia’s biotech ecosystem has emerged as a global launchpad for innovation. Western pharma and biotech companies are increasingly turning to de-risked assets from Asia to supercharge their clinical pipelines and gain a competitive edge.
Already running in the US, the Targeted Therapies Partnering & Licensing Summit Asia is built to gather a regional, critical mass of ADC, Bispecific Antibody, T-Cell Engager, Targeted Protein Degradation, and Radiopharmaceutical platforms and pipelines, so that global multi-national (MNC) pharma can connect with biotech business development and discuss new licensing and co-development opportunities.
For NewCo, private and public biotech or small pharma, this accessible forum offers:
- High seniority and quality of attendees across pharma and other biotech
- Targeted focus, purpose-built format, and One-on-One Partnering™ portal allowing you to make meaningful connections easier and more efficient
- Informative presentations and discussions nuanced to considerations for deal-making across targeted therapies
Global exposure, local advantage. Pharma can assess related programs back-to-back and biotech can meet multiple, international big pharma.
Download the Event Guide
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.